
# CLAIMS

1. Compound represented by



[1]

the above formula [1] wherein $R^1$ and $R^2$ are each independently a branched or straight alkyl group having up to 17 atoms ~~selected from carbon, nitrogen, oxygen and sulphur~~, n is 0 to and including 18, Y is sulphur or selene, X is S or O and R is ~~–OH or~~ an organic group comprising one or more peptides, one or more nucleic acids, one or more antibodies or combinations thereof.

2. Compound according to claim 1, wherein X is O.

3. Compound according to any one of claims 1-2, wherein Y is sulphur.

4. Compound according to any one of claims 1-3, wherein $R^1$ and $R^2$ are each independently a straight alkyl group having 10 to 17 carbon atoms.


5. Compound according to claim 4, wherein $R^1$ and $R^2$ are straight alkyl groups having 15 carbon atoms.

6. Compound according to any one of claims 1-5, wherein n is 11 to and including ~~, 12 or 13~~15.

7. Compound according to any one of claims 1-6, wherein R ~~is an organic group comprising one or more peptides, preferably R~~ is $SK_m$, wherein m is 1, 2, 3, 4 or 5, and wherein R is optionally coupled to an antigen.

8. The compound according to claim 7, wherein $R^1$ and $R^2$ are straight chain alkyl groups having 15 carbon atoms, m is 4, n is 12 or 14, X is O, and Y is sulphur.

~~8~~9 Compound according to claim ~~7~~1, wherein group R is represented by



in which $R^4$ a $K_m$ peptide part, wherein m is 0, 1, 2, 3, 4 or 5, and wherein $R^4$ is optionally coupled to an antigen and in which $R^5$ is hydrogen or a group comprising one to six atoms chosen from carbon, nitrogen and oxygen.

~~9~~10. Compound according to claim ~~8~~9, wherein $R^5$ is a $-CH_2$-OH group, a $-CH_2$-$CH_3$ group, a $-(CH_2)_3$-$CH_3$ group, a $-CH_2C{\equiv}CH$ group, a $-CH_2CH{=}CH_2$ group or a $-(CH_2)_2NH_2$ group.

~~10~~11. Compound according to claim ~~8~~9 or ~~9~~10, wherein $R^5$ is not hydrogen and the asymmetric carbon to which $R^5$ is attached has the L configuration.

~~11~~12. Compound according to any one of claims 7-~~10~~11, wherein the $K_m$ peptide part is coupled to an antigen, a nucleic acid and/or an antibody.

~~12~~13. Solid phase peptide synthesis process to prepare a compound according to any one of claims 1-~~11~~12, comprising

(a) providing R-H, which is optionally immobilized and/or side-chain protected;

(b) coupling of substituted cysteine building block Fmoc-(Y-(2-($OC(O)R^2$)-3-($OC(O)R^1$))propyl)-Cys-OH to R-H; and

(c) cleavage of the Fmoc-group from the N-terminus of the resulting peptide; and

(d) treatment of the Fmoc-liberated peptide with H-$(CH_2)_n$-N=C=X, wherein R, $R^1$, $R^2$, X, Y and n are as defined in any one of claims 1-~~10~~11.

~~13~~14. Process according to claim ~~12~~13, wherein ~~R is an organic group comprising one or more peptides and~~ R-H is immobilized and/or side-chain protected.

~~14~~15. Process according to claim ~~13~~14, further comprising:

(e) conjugating an antibody or a nucleic acid to the H-$(CH_2)_n$-N=C=X-treated peptide.

~~15~~16. Composition comprising the compound according to any one of claims 1-~~11~~12 and an antigen either as separate compound or as part of the compound according to any one of claims 1-~~11~~12.

~~16~~17. Use of the compound according to any one of claims 1 to ~~11~~12 or a composition according to claim ~~15~~16 for the manufacture of a medicament.

~~17~~18. Use of a composition according to claim ~~16~~17, wherein the medicament is for the prevention, delay and/or treatment of a disease or condition selected from a tumor, a disease or damage of the central nervous system, an ischemia and an infection~~wherein the composition is for use as a preventive or therapeutic vaccine against the antigen~~.

~~18~~19. Use of a compound according to any one of claims 1-~~11~~12 and an antigen, either as separate compound or as part of the compound according to any one of claims 1-~~11~~12, for the manufacture of a vaccine composition ~~for the induction, maintenance and/or enhancement of an immune response in a subject against the antigen and/or~~ for the prevention, delay and/or treatment of an infection, a cancer or pre-malignant lesion~~a disease or condition~~ associated with the antigen in a subject.